Get Started

XERS

NASD Xeris Biopharma Holdings, Inc.
Nov 5, 2026 · 9:16 AM ET LAST TRADE Market Closed

$12.14 ↑ +1.68 (+16.08%) Trading Up from the previous close of $10.46

YTD change
+54.67%
vs 20-day SMA
+16.11%
vs 200-day SMA
+60.99%

Price ranges

Previous day
$10.15 $10.71
open $10.52 close $10.46
-$0.06 (-0.57%)
Today
$0.00 $0.00
$12.14
Past week
$10.08 $10.95
from $10.64 now $12.14
+$1.50 (+14.11%)
Past month
$9.73 $11.42
from $10.11 now $12.14
+$2.03 (+20.09%)
This year
$5.25 $11.42
from $7.85 now $12.14
+$4.29 (+54.67%)

Price & Performance

+4.23 (+67.90%) / 6M

$5.47$7.50$9.52$11.55May 5Aug 5Nov 4

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 56.6% away from all-time highs of $27.98
  • XERS is up 55% since the beginning of the year
  • XERS is up 23% over the past 12 months
  • XERS is up 20% over the past 1 month
  • 5% of all XERS investors are betting against XERS

XERS reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +6.0%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.18
Earnings momentum +668.4% Quarterly EPS growth
Quarterly change +668.4%

Valuation

P/E ratio N/A
Enterprise value $2.0B
Beta 0.15

Balance sheet & scale

IncomeN/A
Revenue$335.4M
Cash$121.7M
Debt$289.4K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $2.2B

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Competitor comparison

TickerCompany PriceChange
AMGN Amgen Inc. $478.48 +3.73%
MRNA Moderna, Inc. $258.38 +13.11%
RVMD Revolution Medicines, Inc. $199.70 +2.82%
ROIV Roivant Sciences Ltd. $38.23 +6.08%
BNTX BioNTech SE Sponsored ADR $90.70 +4.35%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.